バイオ医薬品の市場規模、シェア、成長分析、タイプ別、流通チャネル別、用途別、地域別 - 産業予測 2025～2032年

バイオ医薬品市場規模は2023年に5,703億米ドルとなり、2024年の6,085億1,000万米ドルから2032年には1兆223億1,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.7％で成長する見通しです。

市場の洞察によると、バイオ医薬品に対する需要は、世界人口の増加と加齢関連疾患や慢性疾患の増加が相まって拡大しています。世界保健機関（WHO）は、2020年には65歳以上の成人が5歳未満の子供を上回り、この動向は2050年までに同等になると予測しています。この人口動態の変化により、特に高齢者に多いがん、神経疾患、心血管疾患などの疾患を管理するためのヘルスケア・サービスへの需要が高まっています。家族介護と専門家による介護の両方に対するニーズの高まりは、この需要をさらに増幅させ、バイオ医薬品企業による研究開発への投資促進を促しています。さらに、バイオ医薬品に対する規制当局の承認が上昇することで、革新的な治療法への迅速なアクセスが約束され、今後数年間の市場の成長を大きく後押しします。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術の進歩

バイオ医薬品の市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 免疫調節薬
  • モノクローナル抗体
  • サイトカイン
  • インターフェロン
  • その他
• 酵素
  • ヒドロラーゼ
  • リアーゼ
  • 酸化還元酵素
  • その他
• ワクチン
  • 組み換え体/複合体/サブユニット
  • 不活性化
  • 生弱毒化
  • トキソイド
• ホルモン
  • ヒト成長ホルモン
  • インスリン
  • 甲状腺刺激ホルモン
  • その他
• その他

バイオ医薬品の市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• ドラッグストアと薬局
• オンライン薬局

バイオ医薬品の市場規模：用途別& CAGR（2025-2032）

• 市場概要
• 心臓病学
• 腫瘍学
• 呼吸器
• 免疫学
• 神経学
• その他

バイオ医薬品市場規模& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Lonza Group（Switzerland）
• WuXi Biologics（China）
• Fujifilm Diosynth Biotechnologies（Japan）
• Recipharm（Sweden）
• Samsung Biologics（South Korea）
• Boehringer Ingelheim（Germany）
• Catalent（USA）
• Thermo Fisher Scientific（USA）
• Siegfried Holding AG（Switzerland）
• AGC Biologics（Japan）
• WuXi AppTec（China）
• Cambrex Corporation（USA）
• Charles River Laboratories（USA）
• Chugai Pharmaceutical（Japan）
• Biocon Limited（India）
• Dr. Reddy's Laboratories（India）
• Sun Pharmaceutical Industries（India）
• Teva Pharmaceutical Industries（Israel）
• Novartis（Switzerland）

結論と提言

Biopharmaceuticals Market size was valued at USD 570.3 billion in 2023 and is poised to grow from USD 608.51 billion in 2024 to USD 1022.31 billion by 2032, growing at a CAGR of 6.7% during the forecast period (2025-2032).

Market insights reveal a growing demand for biopharmaceuticals, driven by an increasing global population coupled with a rise in age-related diseases and chronic medical conditions. The World Health Organization notes that in 2020, adults aged 65 and older outnumbered children under five, a trend expected to equalize by 2050. This demographic shift is prompting heightened demand for healthcare services, particularly to manage disorders like cancer, neurological conditions, and cardiovascular diseases prevalent among seniors. The rising need for both family and professional care further amplifies this demand, encouraging biopharmaceutical companies to boost investments in research and development. Additionally, an uptick in regulatory approvals for biopharmaceutical products promises expedited access to innovative treatments, significantly propelling the market's growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biopharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biopharmaceuticals Market Segments Analysis

Global Biopharmaceuticals Market is segmented by Type, Distribution Channel, Application and region. Based on Type, the market is segmented into Immunomodulators, Enzymes, Vaccines, Hormones and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on Application, the market is segmented into Cardiology, Oncology, Respiratory, Immunology, Neurology and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biopharmaceuticals Market

A significant driver fueling the growth of the biopharmaceuticals market is the escalating prevalence of chronic diseases worldwide. This alarming rise has prompted governments across various regions to initiate awareness campaigns aimed at educating the public about these conditions, resulting in a heightened focus on treatment options. Consequently, the demand for medications in the biopharmaceutical sector, particularly those targeting specialized areas such as rare, chronic, and hereditary disorders, is expected to see a steady increase. As more individuals become aware of their healthcare options, the market is poised for substantial expansion, driven by the need for effective therapeutic solutions.

Restraints in the Biopharmaceuticals Market

The biopharmaceuticals market faces significant restraints due to the elevated costs associated with development and production. The complex manufacturing processes and stringent regulatory requirements necessitate advanced technologies, resulting in the higher overall expense of biologics. This inflated cost can create barriers to access and limit affordability for numerous patients and healthcare systems. Consequently, the financial challenges linked to the development and formulation of biopharmaceuticals mean that many individuals may not benefit from these innovative therapies, ultimately hindering the market's growth and restricting patient access to essential treatments.

Market Trends of the Biopharmaceuticals Market

The biopharmaceutical market is witnessing a transformative trend in gene and cell therapies, which address pressing healthcare needs, particularly for rare diseases, cancers, and genetic disorders. These innovative therapies are ushering in a new era of personalized medicine, offering potential curative solutions through targeted cell or DNA replacement. The efficacy of these treatments is bolstered by breakthroughs in viral vector delivery systems and CRISPR technology, enhancing precision and outcomes. However, challenges related to high costs and navigating regulatory approvals remain prominent. As research and development efforts continue, the market is anticipated to expand significantly, revolutionizing patient care and treatment paradigms.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Biopharmaceuticals Market Size by Type & CAGR (2025-2032)

• Market Overview
• Immunomodulators
  • Monoclonal Antibodies
  • Cytokines
  • Interferons
  • Others
• Enzymes
  • Hyrdolases
  • Lyases
  • Oxidoreductases
  • Others
• Vaccines
  • Recombinant/Conjugate/Subunit
  • Inactivated
  • Live Attenuated
  • Toxoid
• Hormones
  • Human Growth Hormones
  • Insulin
  • Thyroid Stimulating Hormones
  • Others
• Others

Global Biopharmaceuticals Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Global Biopharmaceuticals Market Size by Application & CAGR (2025-2032)

• Market Overview
• Cardiology
• Oncology
• Respiratory
• Immunology
• Neurology
• Others

Global Biopharmaceuticals Market Size & CAGR (2025-2032)

• North America (Type, Distribution Channel, Application)
  • US
  • Canada
• Europe (Type, Distribution Channel, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Distribution Channel, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Distribution Channel, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Distribution Channel, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth Biotechnologies (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siegfried Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cambrex Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations